Sotera Health Company — Form 8-K Summary
Business context and reporting period
Sotera Health Company filed a Form 8-K dated March 31, 2021, reporting entry into a material amendment to its first-lien revolving credit facility on March 26, 2021. The filing does not report quarterly operating results for the period ended March 31, 2021.
Key financial and financing metrics
| Metric | Reported information |
|---|---|
| Revolving commitments | $347.5 million; unchanged by the amendment |
| Revolving loans outstanding | None at December 31, 2020 or March 31, 2021 |
| Revolving facility maturity | Extended from December 13, 2024 to June 13, 2026 |
| ABR loan pricing | Reduced from a leverage-based range of ABR plus 2.50% to 3.00% to ABR plus 1.75% |
| Eurodollar loan pricing | Reduced from a leverage-based range of Adjusted LIBO Rate plus 3.50% to 4.00% to Adjusted LIBO Rate plus 2.75% |
The filing text does not provide revenue, profit, cash flow, operating margins, total debt, cash balances, or liquidity beyond the revolving commitment and undrawn status described above.
Material changes versus the prior comparable period
- The amendment reduced the applicable interest-rate margins on revolving borrowings.
- The revolving facility maturity was extended by 18 months to June 13, 2026.
- The aggregate revolving commitments and other material credit agreement terms were unchanged.
- No revolving loans were outstanding at either December 31, 2020 or March 31, 2021.
Guidance, outlook, risks, contingencies, and unusual items
No management guidance, operating outlook, risk update, contingency, or unusual operating item was disclosed. The amendment may reduce future borrowing costs and extend committed financing availability, but the filing does not quantify any expected financial impact.
The amendment will be filed as an exhibit to the company’s next Quarterly Report on Form 10-Q. The filing states that its description of the amendment and underlying credit agreement is not complete and is qualified by the full agreements.
Important facts for investors to verify
- Confirm the final terms in the Revolving Facilities Amendment when filed with the next Form 10-Q.
- Review the company’s Form 10-Q for total debt, cash, leverage ratios, covenant compliance, and borrowing capacity.
- Assess whether the reduced pricing and extended maturity materially affect interest expense and liquidity.
- Verify whether any revolving borrowings were incurred after March 31, 2021.